Brokerages Set Exact Sciences Corporation (NASDAQ:EXAS) Target Price at $92.13

Exact Sciences Corporation (NASDAQ:EXAS) has been given a consensus rating of “Reduce” by the twenty-two brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and twenty-one have assigned a hold recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $92.1250.

Several equities research analysts have issued reports on EXAS shares. William Blair downgraded Exact Sciences from an “outperform” rating to a “market perform” rating in a report on Thursday, November 20th. Zacks Research lowered Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Mizuho reiterated a “neutral” rating and issued a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a research report on Tuesday, January 20th. Citigroup cut Exact Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, November 20th. Finally, Leerink Partners downgraded shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $103.57 on Monday. The stock has a 50-day moving average of $102.83 and a 200-day moving average of $84.12. Exact Sciences has a one year low of $38.81 and a one year high of $103.75. The stock has a market cap of $19.77 billion, a PE ratio of -94.15, a price-to-earnings-growth ratio of 2.36 and a beta of 1.41. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The firm’s revenue was up 23.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.06) EPS. As a group, sell-side analysts expect that Exact Sciences will post -0.58 earnings per share for the current year.

Institutional Investors Weigh In On Exact Sciences

Institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Exact Sciences in the 1st quarter valued at about $604,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Exact Sciences by 11.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,186 shares of the medical research company’s stock worth $921,000 after buying an additional 2,231 shares during the period. Great Lakes Advisors LLC grew its holdings in shares of Exact Sciences by 3.7% during the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock worth $215,000 after buying an additional 178 shares in the last quarter. Focus Partners Wealth grew its holdings in shares of Exact Sciences by 12.6% during the first quarter. Focus Partners Wealth now owns 21,548 shares of the medical research company’s stock worth $933,000 after buying an additional 2,413 shares in the last quarter. Finally, Assetmark Inc. raised its position in Exact Sciences by 34.2% in the 2nd quarter. Assetmark Inc. now owns 3,346 shares of the medical research company’s stock valued at $178,000 after buying an additional 852 shares during the last quarter. 88.82% of the stock is owned by institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.